JP2014510157A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014510157A5 JP2014510157A5 JP2014504053A JP2014504053A JP2014510157A5 JP 2014510157 A5 JP2014510157 A5 JP 2014510157A5 JP 2014504053 A JP2014504053 A JP 2014504053A JP 2014504053 A JP2014504053 A JP 2014504053A JP 2014510157 A5 JP2014510157 A5 JP 2014510157A5
- Authority
- JP
- Japan
- Prior art keywords
- hydrogen
- methyl
- pharmaceutically acceptable
- aliphatic
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims description 56
- 239000001257 hydrogen Substances 0.000 claims description 54
- 150000001875 compounds Chemical class 0.000 claims description 46
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 44
- 125000001931 aliphatic group Chemical group 0.000 claims description 40
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 32
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 28
- 150000003839 salts Chemical class 0.000 claims description 27
- 206010028980 Neoplasm Diseases 0.000 claims description 18
- 201000011510 cancer Diseases 0.000 claims description 18
- 201000010099 disease Diseases 0.000 claims description 16
- 208000035475 disorder Diseases 0.000 claims description 16
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 13
- 150000002431 hydrogen Chemical class 0.000 claims description 12
- 229910052736 halogen Inorganic materials 0.000 claims description 8
- 150000002367 halogens Chemical group 0.000 claims description 8
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 125000002252 acyl group Chemical group 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 230000001394 metastastic effect Effects 0.000 claims description 4
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 125000002837 carbocyclic group Chemical group 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000001072 heteroaryl group Chemical group 0.000 claims description 2
- 125000000623 heterocyclic group Chemical group 0.000 claims description 2
- 125000001183 hydrocarbyl group Chemical group 0.000 claims description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 2
- 229920006395 saturated elastomer Polymers 0.000 claims description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 11
- 239000003814 drug Substances 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 208000024891 symptom Diseases 0.000 description 2
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161473131P | 2011-04-07 | 2011-04-07 | |
| US61/473,131 | 2011-04-07 | ||
| US201161508275P | 2011-07-15 | 2011-07-15 | |
| US61/508,275 | 2011-07-15 | ||
| PCT/US2012/032642 WO2012139074A2 (en) | 2011-04-07 | 2012-04-06 | Migrastatins and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016113255A Division JP2016155873A (ja) | 2011-04-07 | 2016-06-07 | ミグラスタチンおよびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014510157A JP2014510157A (ja) | 2014-04-24 |
| JP2014510157A5 true JP2014510157A5 (cg-RX-API-DMAC7.html) | 2015-05-21 |
| JP5975581B2 JP5975581B2 (ja) | 2016-08-23 |
Family
ID=46969857
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014504053A Expired - Fee Related JP5975581B2 (ja) | 2011-04-07 | 2012-04-06 | ミグラスタチンおよびその使用 |
| JP2016113255A Withdrawn JP2016155873A (ja) | 2011-04-07 | 2016-06-07 | ミグラスタチンおよびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016113255A Withdrawn JP2016155873A (ja) | 2011-04-07 | 2016-06-07 | ミグラスタチンおよびその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US9303009B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2693879B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP5975581B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN103635088B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2012239977B9 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2832439C (cg-RX-API-DMAC7.html) |
| WO (1) | WO2012139074A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5975581B2 (ja) | 2011-04-07 | 2016-08-23 | スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ | ミグラスタチンおよびその使用 |
| US10285646B1 (en) * | 2018-02-27 | 2019-05-14 | CeriBell, Inc. | Connection quality assessment for EEG electrode arrays |
| AU2019329835B2 (en) | 2018-08-27 | 2025-05-29 | Spinogenix, Inc. | Fascin binding compounds for spinogenesis |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004087673A2 (en) | 2003-03-28 | 2004-10-14 | Sloan-Kettering Institute For Cancer Research | Migrastatin analogs and uses thereof |
| US20070037783A1 (en) | 2003-03-28 | 2007-02-15 | Xin-Yun Huang | Migrastatin analogs and uses thereof |
| WO2005019181A1 (en) | 2003-08-19 | 2005-03-03 | Cornell Research Foundation, Inc. | Migrastatin analog cell migration inhibitors |
| WO2006001967A2 (en) | 2004-05-25 | 2006-01-05 | Sloan-Kettering Institute For Cancer Research | Migrastatin analogs in the treatment of cancer |
| US8188141B2 (en) * | 2004-09-23 | 2012-05-29 | Sloan-Kettering Institute For Cancer Research | Isomigrastatin analogs in the treatment of cancer |
| CN101918036A (zh) | 2007-11-21 | 2010-12-15 | 康奈尔大学 | 抑制肌成束蛋白的方法 |
| JP5975581B2 (ja) | 2011-04-07 | 2016-08-23 | スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ | ミグラスタチンおよびその使用 |
-
2012
- 2012-04-06 JP JP2014504053A patent/JP5975581B2/ja not_active Expired - Fee Related
- 2012-04-06 EP EP12768014.8A patent/EP2693879B1/en active Active
- 2012-04-06 AU AU2012239977A patent/AU2012239977B9/en not_active Ceased
- 2012-04-06 CA CA2832439A patent/CA2832439C/en not_active Expired - Fee Related
- 2012-04-06 CN CN201280027680.5A patent/CN103635088B/zh not_active Expired - Fee Related
- 2012-04-06 WO PCT/US2012/032642 patent/WO2012139074A2/en not_active Ceased
- 2012-04-06 US US14/110,115 patent/US9303009B2/en not_active Expired - Fee Related
-
2016
- 2016-03-09 US US15/065,090 patent/US9546146B2/en not_active Expired - Fee Related
- 2016-06-07 JP JP2016113255A patent/JP2016155873A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10166246B2 (en) | TGR5 agonist complexes for treating diabetes and cancer | |
| JP2019500327A5 (cg-RX-API-DMAC7.html) | ||
| AU2018360766B2 (en) | Anticancer agents | |
| JP2016515561A5 (cg-RX-API-DMAC7.html) | ||
| JP2016512563A5 (cg-RX-API-DMAC7.html) | ||
| RU2008126305A (ru) | Новый пептид | |
| RU2009138325A (ru) | Способ получения кристаллов | |
| EP4045498B1 (en) | Broad spectrum anti-cancer compounds | |
| JP2013500304A5 (cg-RX-API-DMAC7.html) | ||
| ME02400B (me) | Policiklična karbamoilpiridonska jedinjenja i njihova farmaceutska upotreba | |
| JP2011523412A5 (cg-RX-API-DMAC7.html) | ||
| JP2016506916A5 (cg-RX-API-DMAC7.html) | ||
| JP2014511892A5 (cg-RX-API-DMAC7.html) | ||
| PE20130396A1 (es) | N-etil-n-fenil-1,2-dihidro-4-hidroxi-5-cloro-1-metil-2-oxoquinolina-3-carboxamida deuterada, sales y usos de la misma | |
| JP2013509389A5 (cg-RX-API-DMAC7.html) | ||
| JP2013542992A5 (cg-RX-API-DMAC7.html) | ||
| JP2018510132A5 (cg-RX-API-DMAC7.html) | ||
| PH12017500136A1 (en) | Long-chain dimethylaniline derivative compounds, their preparation methods, self-assembled textures, and uses thereof | |
| BR112013028679A2 (pt) | inibidores do vírus da hepatite c | |
| JP2017503014A5 (cg-RX-API-DMAC7.html) | ||
| EP4125843B1 (en) | Treatment of hyperinflammatory syndrome | |
| CO7101247A2 (es) | Formulaciones de ácido poliinosínico-policitidílico (poli(i:c)) para el tratamiento de infecciones de las vías respiratorias altas | |
| JP2015517512A5 (cg-RX-API-DMAC7.html) | ||
| JP2014510157A5 (cg-RX-API-DMAC7.html) | ||
| RU2016111704A (ru) | Производные дезоксинойиримицина и способы их применения |